Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

Only two patients receiving placebo attained the iPTH end point.

There were no clinically relevant differences in serum calcium (Ca) or phosphorus (P) levels between the group treated with paricalcitol and that treated with placebo.

Who Took Part

According to the abstract, 35 patients were involved.

PubMed indexes the participants as teenagers, adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Parathyroid Hormone (PTH 1-84).

Some patients received a placebo instead of Parathyroid Hormone (PTH 1-84), giving a reference point.

More than one site took part, so the patients came from several places.

What Was Measured

Only two patients receiving placebo attained the iPTH end point.

There were no clinically relevant differences in serum calcium (Ca) or phosphorus (P) levels between the group treated with paricalcitol and that treated with placebo.

The subject headings attached to it are Calcium, Ergocalciferols, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Parathyroid Hormone, Phosphorus and Renal Dialysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 35 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1998 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.